Viatris Outlines Long-Term Financial Targets Through 2030
MT Newswires Live
Mar 19
Viatris (VTRS) said Thursday it projects a compound annual growth rate for total revenue of 5% to 6% through 2030.
The pharmaceutical firm's long-term financial goals also include an adjusted earnings per share compound annual growth rate between 9% and 10%, alongside over $3 billion in annual free cash flow by the end of the decade, it said.
A recent strategic review outlined roughly $650 million in gross cost reductions across a three-year span, while the company anticipates generating more than $11 billion in available capital for allocation through 2030, Viatris said.
The company also said it plans to launch Meloxicam in the US, and Pitolisant and Effexor in Japan in the near term.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.